DE122007000021I1 - Anti-vefg Antibodies - Google Patents

Anti-vefg Antibodies

Info

Publication number
DE122007000021I1
DE122007000021I1 DE200712000021 DE122007000021C DE122007000021I1 DE 122007000021 I1 DE122007000021 I1 DE 122007000021I1 DE 200712000021 DE200712000021 DE 200712000021 DE 122007000021 C DE122007000021 C DE 122007000021C DE 122007000021 I1 DE122007000021 I1 DE 122007000021I1
Authority
DE
Germany
Prior art keywords
vefg
antibodies
anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE200712000021
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US83350497A priority Critical
Priority to US08/908,469 priority patent/US6884879B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to PCT/US1998/006604 priority patent/WO1998045331A2/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27125626&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122007000021(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of DE122007000021I1 publication Critical patent/DE122007000021I1/de
Application status is Pending legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
DE200712000021 1997-04-07 1998-04-03 Anti-vefg Antibodies Pending DE122007000021I1 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US83350497A true 1997-04-07 1997-04-07
US08/908,469 US6884879B1 (en) 1997-04-07 1997-08-06 Anti-VEGF antibodies
PCT/US1998/006604 WO1998045331A2 (en) 1997-04-07 1998-04-03 Anti-vegf antibodies

Publications (1)

Publication Number Publication Date
DE122007000021I1 true DE122007000021I1 (de) 2007-05-24

Family

ID=27125626

Family Applications (5)

Application Number Title Priority Date Filing Date
DE200512000026 Pending DE122005000026I1 (de) 1997-04-07 1998-04-03 Anti-VEGF Antik¦rper.
DE69836729T Expired - Lifetime DE69836729T2 (de) 1997-04-07 1998-04-03 Anti-vefg antibodies
DE200712000021 Pending DE122007000021I1 (de) 1997-04-07 1998-04-03 Anti-vefg Antibodies
DE69829891T Expired - Lifetime DE69829891T2 (de) 1997-04-07 1998-04-03 Anti-VEGF Antikörper
DE200512000050 Pending DE122005000050I1 (de) 1997-04-07 2005-05-25 Anti-Vegf Antik¦rper.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE200512000026 Pending DE122005000026I1 (de) 1997-04-07 1998-04-03 Anti-VEGF Antik¦rper.
DE69836729T Expired - Lifetime DE69836729T2 (de) 1997-04-07 1998-04-03 Anti-vefg antibodies

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69829891T Expired - Lifetime DE69829891T2 (de) 1997-04-07 1998-04-03 Anti-VEGF Antikörper
DE200512000050 Pending DE122005000050I1 (de) 1997-04-07 2005-05-25 Anti-Vegf Antik¦rper.

Country Status (23)

Country Link
US (2) US7060269B1 (de)
EP (4) EP1325932B9 (de)
JP (1) JP3957765B2 (de)
KR (2) KR100816621B1 (de)
CN (1) CN100480269C (de)
AT (2) AT349470T (de)
AU (1) AU743758B2 (de)
BR (1) BRPI9809387B1 (de)
CA (1) CA2286330C (de)
DE (5) DE122005000026I1 (de)
DK (2) DK0973804T3 (de)
ES (2) ES2273415T3 (de)
HK (2) HK1084402A1 (de)
IL (1) IL132240D0 (de)
LT (1) LTPA2005005I1 (de)
LU (2) LU91167I2 (de)
NL (2) NL300193I2 (de)
NO (3) NO324264B1 (de)
NZ (1) NZ500078A (de)
PT (1) PT1325932E (de)
SI (1) SI1325932T1 (de)
TR (1) TR199903123T2 (de)
WO (1) WO1998045331A2 (de)

Families Citing this family (377)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6171820B1 (en) * 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US7018793B1 (en) 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
US20070059302A1 (en) * 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
DE122005000026I1 (de) 1997-04-07 2005-08-04 Genentech Inc Anti-VEGF Antik¦rper.
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
EP2077276A1 (de) 2000-06-23 2009-07-08 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
EP2792747A1 (de) 2000-06-23 2014-10-22 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
EP1950300A3 (de) 1998-11-18 2011-03-23 Genentech, Inc. Antikörpervarianten mit höherer Bindungsaffinität im Vergleich zu verwandten Antikörpern
US6632926B1 (en) * 1998-11-18 2003-10-14 Genentech, Inc. Antibody variants
WO2000034337A1 (en) * 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
DE69926536T3 (de) 1998-12-22 2013-09-12 Genentech, Inc. Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6887468B1 (en) 1999-04-28 2005-05-03 Board Of Regents, The University Of Texas System Antibody kits for selectively inhibiting VEGF
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
JP2003508027A (ja) * 1999-07-29 2003-03-04 エピックス メディカル, インコーポレイテッド フィブリン結合性部分
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
CA2921260A1 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
EP1757701A1 (de) 1999-12-24 2007-02-28 Genentech, Inc. Verfahren und Zusammensetzungen zur Verlängerung der Halbzeiten der Entfernung von biowirksamen Verbindungen
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
US6989138B2 (en) 2000-10-24 2006-01-24 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers and hydrophilic 6-hydroxy chromans
US6902718B2 (en) 2000-10-24 2005-06-07 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
TWI240632B (en) 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
BR0213761A (pt) * 2001-10-25 2005-04-12 Genentech Inc Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
DE60325334D1 (de) 2002-02-05 2009-01-29 Genentech Inc Proteinaufreinigung
SI1501369T1 (sl) 2002-04-26 2015-10-30 Genentech, Inc. Neafinitetno čiščenje proteinov
JP4563171B2 (ja) * 2002-05-24 2010-10-13 シェーリング コーポレイションSchering Corporation 中和ヒト抗igfr抗体
AU2003247869C1 (en) 2002-07-15 2009-12-24 Board Of Regents, The University Of Texas System Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1585768A2 (de) 2003-01-23 2005-10-19 Genentech, Inc. Verfahren zur herstellung von menschlischen antikörpern und zur steigerung der ausbeute von antikörpern oder von antigenbindenden fragmenten in zellkultur
US7491509B2 (en) 2003-02-03 2009-02-17 Fraunhofer Usa, Inc. System for expression of genes in plants
WO2004080418A2 (en) 2003-03-12 2004-09-23 Vasgene Therapeutics, Inc. Nucleic acid compounds for inhibiting angiogenesis and tumor growth
AT492564T (de) 2004-03-12 2011-01-15 Vasgene Therapeutics Inc Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1730196B1 (de) 2004-03-12 2010-12-22 Vasgene Therapeutics, Inc. Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
US8431396B2 (en) 2003-03-21 2013-04-30 The Cleveland Clinic Foundation Anti-angiogenic peptides
EP1664322B1 (de) 2003-05-22 2013-07-10 Fraunhofer USA, Inc. Rekombinantes trägermolekül zur expression, zuführung und reinigung von zielpolypeptiden
NZ621449A (en) * 2003-05-30 2015-07-31 Genentech Inc Treatment with anti-vegf antibodies
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
EP1648940B1 (de) 2003-07-28 2016-04-27 Genentech, Inc. Verminderung des auswaschens von protein a während der protein-a-affinitätschromatographie
WO2005012531A2 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
SI1660057T1 (sl) 2003-08-27 2012-10-30 Ophthotech Corp Kombinirana terapija za zdravljenje okularnih neovaskularnih nepravilnosti
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
NZ548828A (en) 2004-01-20 2009-07-31 Merus B V Mixtures of binding proteins
ES2337473T3 (es) 2004-02-19 2010-04-26 Genentech, Inc. Anticuerpos reparadores con cdr.
TW200607523A (en) 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
US20060270922A1 (en) 2004-07-13 2006-11-30 Brauker James H Analyte sensor
US7885697B2 (en) 2004-07-13 2011-02-08 Dexcom, Inc. Transcutaneous analyte sensor
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
EP2172482A1 (de) * 2004-07-20 2010-04-07 Genentech, Inc. Angiopoietin-like 4 Protein Hemmer Kombinationen und deren Verwendung
ES2531155T3 (es) 2004-07-23 2015-03-11 Genentech Inc Cristalización de anticuerpos anti-VEGF
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
WO2006034455A2 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
DK1802334T3 (da) 2004-10-21 2012-10-15 Genentech Inc Fremgangsmåde til behandling af intraokulære, neovaskulære sygdomme
EP1833970A2 (de) 2004-12-22 2007-09-19 Genentech, Inc. Verfahren zur herstellung löslicher, mehrere membranen überspannender proteine
US8236283B2 (en) * 2005-01-06 2012-08-07 Ge Healthcare As Optical imaging
EP3248600A1 (de) 2005-02-18 2017-11-29 Abraxis BioScience, LLC Kombinationen und modi zur verabreichung therapeutischer mittel und kombinationstherapie
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
EP1879587A2 (de) * 2005-04-15 2008-01-23 Schering Corporation Verfahren und zusammensetzungen zur behandlung oder vorbeugung von krebs
US20080045949A1 (en) * 2005-06-17 2008-02-21 Hunt Margaret M Method of treating degenerative spinal disorders
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ES2373080T3 (es) * 2005-06-20 2012-01-31 Genentech, Inc. Anticuerpos que se unen al antígeno tat10772 asociado a tumores para el diagnóstico y tratamiento de un tumor.
JP2009502207A (ja) 2005-08-03 2009-01-29 フラウンホーファー ユーエスエー, インコーポレイテッド イムノグロブリンの産生のための組成物および方法
DK1931321T3 (en) 2005-08-31 2019-04-15 Abraxis Bioscience Llc Compositions containing very water-soluble pharmaceutical and antimicrobial agents
MY154904A (en) 2005-11-08 2015-08-28 Genentech Inc Neuropilin antagonists
KR100877824B1 (ko) 2005-11-11 2009-01-12 한국생명공학연구원 E2epf ucp-vhl 상호작용 및 그 용도
JP5199108B2 (ja) * 2005-11-14 2013-05-15 ユニヴァーシティー オブ サザン カリフォルニア インテグリン結合小分子
TW200804425A (en) * 2005-12-06 2008-01-16 Domantis Ltd Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
US20080107648A1 (en) 2005-12-16 2008-05-08 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with DII4 antagonists
ES2526204T3 (es) 2006-01-05 2015-01-08 Genentech, Inc. Anticuerpos anti-EphB4 y métodos para usar los mismos
EP1976884B1 (de) 2006-01-20 2012-12-19 Genentech, Inc. Anti-ephrinb2-antikörper sowie verfahren zu ihrer verwendung
US8124103B2 (en) 2006-02-13 2012-02-28 Fraunhofer Usa, Inc Influenza antigens, vaccine compositions, and related methods
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
NZ571068A (en) 2006-03-21 2012-06-29 Genentech Inc An antibody that can bind human alpha5beta1
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
US20070264193A1 (en) * 2006-03-29 2007-11-15 Genentech, Inc. Diagnostics and treatments for tumors
BRPI0710411A2 (pt) * 2006-06-06 2012-04-10 Genentch Inc Empresa Americana métodos para tratar um tumor, para tratar uma condição patológica associada à angiogênese, para estimular a proliferação celular endotelial, para reduzir ou inibir a diferenciação celular endotelial, para reduzir ou inibir o desenvolvimento arterial, para reduzir ou inibir a perfusão vascular tumoral para aumentar a eficácia de um agente anti-angiogênico, usos de um antagonista de dll4 e uso de um agonisra de dll4
KR20090027227A (ko) 2006-06-06 2009-03-16 제넨테크, 인크. 항-dll4 항체 및 이의 사용 방법
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
EP2068877A4 (de) 2006-07-19 2011-09-21 Cleveland Clinic Foundation Verbindungen und verfahren zur modulierung von angiogenese
CN100448892C (zh) * 2006-08-02 2009-01-07 中国人民解放军军事医学科学院基础医学研究所 抗肿瘤血管内皮生长因子受体VEGF-R<sub>2</sub>抗原及其编码基因与应用
BRPI0715829A2 (pt) 2006-08-21 2013-07-23 Hoffmann La Roche terapia de tumor com um anticorpo anti-vegf
WO2008042236A2 (en) 2006-09-29 2008-04-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
ES2470682T3 (es) 2006-10-04 2014-06-24 Genentech, Inc. ELISA para VEGF
JP2010507594A (ja) * 2006-10-20 2010-03-11 シェーリング コーポレイションSchering Corporation 完全ヒト抗vegf抗体および使用方法
TWI577695B (zh) 2006-12-19 2017-04-11 建南德克公司 用於輔助及先導性輔助療法之血管內皮生長因子(vegf)-特異性拮抗劑及早期腫瘤之治療
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
ES2426158T3 (es) 2007-01-22 2013-10-21 Genentech, Inc. Precipitación con polielectrolito y purificación de anticuerpos
JP2010517944A (ja) * 2007-01-26 2010-05-27 バイオインヴェント インターナショナル アーベー Dll4シグナリング阻害薬およびその使用
EP2468776A3 (de) 2007-02-09 2012-11-14 Genentech, Inc. Antikörper gegen Robo4 und Anwendungen davon
CA2683568A1 (en) 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
AU2007353778B9 (en) 2007-05-17 2014-04-03 Genentech, Inc. Inhibition of tumor metastasis by anti neuropilin 2 antibodies
PE03212009A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
SG10201406411XA (en) 2007-07-09 2014-11-27 Genentech Inc Prevention of disulfide bond reduction during recombinant production of polypeptides
EP2178558B1 (de) 2007-07-11 2014-04-30 iBio, Inc. Yersinia pestis-antigene, impfstoffzusammensetzungen und zugehörige verfahren
JP5749009B2 (ja) 2007-08-13 2015-07-15 バスジーン セラピューティクス,インコーポレイテッドVasgenetherapeutics,Inc. EphB4に結合するヒト化抗体を利用する癌治療剤
EP3492488A1 (de) 2007-08-22 2019-06-05 The Regents of The University of California Aktivierbare bindende polypeptide und verfahren zu deren identifikation und anwendung
MX2010004740A (es) * 2007-10-30 2010-05-27 Genentech Inc Purificacion de anticuerpos por cromatografia de intercambio cationico.
KR101502267B1 (ko) 2007-11-09 2015-03-18 페레그린 파마수티컬즈, 인크 항-vegf 항체 조성물 및 방법
AR070032A1 (es) 2007-11-09 2010-03-10 Genentech Inc Composiciones y metodos de uso de antagonistas quinasa-1 similar al receptor de la activina (alk-1)
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗-vegf抗體
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
MY166446A (en) 2008-03-18 2018-06-27 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents,and methods of use
JP5425180B2 (ja) * 2008-03-27 2014-02-26 ザイモジェネティクス, インコーポレイテッド PDGFRβおよびVEGF−Aを阻害するための組成物および方法
EP2280997A2 (de) * 2008-04-18 2011-02-09 Xencor, Inc. Aus nichthumanen variablen regionen gentechnisch hergestellte humanäquivalente monoklonale antikörper
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
RU2010153578A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойными вариабельными доменами и их применение
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
ES2622470T3 (es) 2008-06-25 2017-07-06 Esbatech, An Alcon Biomedical Research Unit Llc Anticuerpos estables y solubles que inhiben el VEGF
RU2011104348A (ru) * 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
JP5606438B2 (ja) 2008-07-23 2014-10-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 抗血管新生療法を受容可能な被験体の同定
WO2010019148A1 (en) 2008-08-14 2010-02-18 Genentech, Inc. Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
JP2012501188A (ja) * 2008-08-29 2012-01-19 ジェネンテック, インコーポレイテッド Vegf非依存性腫瘍についての診断薬および治療
EP2331133A4 (de) 2008-09-05 2012-09-12 Univ Duke Anti-lipid-antikörper
BRPI0918978A2 (pt) 2008-09-10 2015-12-01 Genentech Inc composições e métodos a prevenção da degradação oxidativa das proteínas
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
TWI572359B (zh) 2008-10-14 2017-03-01 建南德克公司 免疫球蛋白變異體及其用途
AU2009313475B2 (en) 2008-11-05 2016-06-02 Genentech, Inc. Genetic polymorphisms in age-related macular degeneration
KR20170015525A (ko) 2008-11-22 2017-02-08 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-vegf 항체의 용도
WO2010074953A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Stirred tank reactor and method
WO2010074702A1 (en) 2008-12-16 2010-07-01 Millipore Corporation Purification of proteins
EP2382472B1 (de) 2008-12-23 2015-05-06 F.Hoffmann-La Roche Ag Verfahren und zusammensetzungen zur diagnostischen verwendung bei krebspatienten
EP3543256A1 (de) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modifizierte antikörperzusammensetzungen, verfahren zur herstellung und verwendung davon
WO2010081838A2 (en) 2009-01-14 2010-07-22 Novartis Ag Sterile prefilled container
JP2012517434A (ja) 2009-02-06 2012-08-02 ザ ジェネラル ホスピタル コーポレイション 血管病変を治療する方法
EP2398494A4 (de) * 2009-02-23 2015-10-28 Cytomx Therapeutics Inc Proproteine und anwendungsverfahren dafür
CA2752884A1 (en) 2009-02-27 2010-09-02 Genentech, Inc. Methods and compositions for protein labelling
KR101739598B1 (ko) 2009-03-13 2017-06-08 아브락시스 바이오사이언스, 엘엘씨 티오콜키신 유도체와의 조합 요법
MX2011010012A (es) 2009-03-25 2011-12-06 Genentech Inc NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
SG175004A1 (en) 2009-04-02 2011-11-28 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
WO2010115589A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Trivalent, bispecific antibodies
SG175181A1 (en) * 2009-04-16 2011-11-28 Abbott Biotherapeutics Corp ANTI-TNF-a ANTIBODIES AND THEIR USES
KR20120096401A (ko) * 2009-04-20 2012-08-30 엔에스에이비피 파운데이션, 인크. 아주반트 암 요법
CA2759233C (en) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CA2761310C (en) 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
CA2665956A1 (en) * 2009-05-07 2010-11-07 Samir Patel Combination treatment for ocular diseases
KR20120005021A (ko) 2009-05-08 2012-01-13 제넨테크, 인크. 인간화 항-egfl7 항체 및 그의 사용 방법
NZ596136A (en) 2009-05-08 2013-12-20 Vaccinex Inc Anti-cd100 antibodies and methods for using the same
JP5925677B2 (ja) 2009-06-15 2016-06-01 アイコン・ジェネティクス・ゲーエムベーハー キシロシルトランスフェラーゼ活性の欠損したベンサミアナタバコ(Nicotianabenthamiana)植物
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
KR20120106935A (ko) 2009-07-13 2012-09-27 제넨테크, 인크. 암의 치료를 위한 진단 방법 및 조성물
AR078060A1 (es) 2009-07-14 2011-10-12 Novartis Ag Descontaminacion de superficie de contenedores previamente llenados en empaque secundario
WO2011014457A1 (en) 2009-07-27 2011-02-03 Genentech, Inc. Combination treatments
CN102498129B (zh) * 2009-07-31 2016-03-02 霍夫曼-拉罗奇有限公司 使用bv8拮抗剂或g-csf拮抗剂抑制肿瘤转移
JP5930542B2 (ja) 2009-08-11 2016-06-08 ジェネンテック, インコーポレイテッド グルタミンフリー細胞培養培地におけるタンパク質の生産
JP2013501526A (ja) 2009-08-14 2013-01-17 ジェネンテック, インコーポレイテッド Vegfアンタゴニストに対する患者の応答をモニターするための生物学的マーカー
MX336476B (es) 2009-08-15 2016-01-20 Genentech Inc Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado.
JP5787891B2 (ja) 2009-09-01 2015-09-30 ジェネンテック, インコーポレイテッド 改変されたプロテインa溶離による向上したタンパク質精製
WO2011028642A1 (en) 2009-09-04 2011-03-10 University Of Louisville Research Foundation, Inc. Genetic determinants of prostate cancer risk
WO2011032013A1 (en) 2009-09-11 2011-03-17 Genentech, Inc. Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
SG179196A1 (en) 2009-09-16 2012-04-27 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
MX2012002909A (es) 2009-09-17 2012-04-19 Hoffmann La Roche Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
EP2483307A1 (de) 2009-09-29 2012-08-08 Fraunhofer USA, Inc. Influenza-hämagglutinin-antikörper, zusammensetzungen daraus und zugehörige verfahren
EP3072526B1 (de) 2009-10-16 2018-09-26 Oncomed Pharmaceuticals, Inc. Therapeutische kombination und verwendung mit dll4-antagonistische antikörper und mittel gegen bluthochdruck
DK2491134T3 (en) 2009-10-21 2017-09-18 Genentech Inc Genetic polymorphisms in age-related macular degeneration
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
TWI505836B (zh) 2009-12-11 2015-11-01 Genentech Inc 抗-vegf-c抗體及其使用方法
SG181834A1 (en) 2009-12-21 2012-07-30 Genentech Inc Antibody formulation
US8771685B2 (en) 2009-12-23 2014-07-08 F. Hoffmann-La Roche Ag Anti-BV8 antibodies and uses thereof
US20130178608A1 (en) 2009-12-29 2013-07-11 Samir Kulkarni Protein purification by ion exchange
US20120309056A1 (en) 2010-02-04 2012-12-06 Leon Arnaud Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
CA2787952C (en) 2010-02-23 2016-07-26 Genentech, Inc. Anti-angiogenesis therapy for the treatment of ovarian cancer
ES2722201T3 (es) 2010-03-22 2019-08-08 Hoffmann La Roche Composiciones y procedimientos útiles para estabilizar formulaciones que contienen proteínas
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
EP2552415B1 (de) 2010-03-29 2016-09-07 Abraxis BioScience, LLC Verfahren zur behandlung von karzinomen
EP2560641A2 (de) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Krebstherapie mit einer kombination aus hsp90-hemmerverbindungen und einem vegf-hemmer
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
MX2012012743A (es) 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
KR101827855B1 (ko) 2010-05-17 2018-02-12 이엠디 밀리포어 코포레이션 생체분자 정제용 자극 반응성 중합체
RU2614125C2 (ru) 2010-05-28 2017-03-22 Дженентек, Инк. Снижение уровня лактата и увеличение продукции полипептида путем ингибирования экспрессии лактатдегидрогеназы и киназы пируватдегидрогеназы
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
KR20180049180A (ko) 2010-06-04 2018-05-10 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
WO2011163458A2 (en) 2010-06-24 2011-12-29 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
CA2799472A1 (en) * 2010-07-02 2012-01-05 Genentech, Inc. Treatment of vascularized pigment epithelial detachment with anti-vegf therapy
CN103097418A (zh) 2010-07-09 2013-05-08 霍夫曼-拉罗奇有限公司 抗神经毡蛋白抗体及使用方法
WO2012010551A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
EP2596362A1 (de) 2010-07-19 2013-05-29 F. Hoffmann-La Roche AG Verfahren zur identifizierung eines patienten mit erhöhter wahrscheinlichkeit des ansprechens auf eine antitumortherapie
WO2012018790A2 (en) 2010-08-03 2012-02-09 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
JP2013537539A (ja) 2010-08-13 2013-10-03 ジェネンテック, インコーポレイテッド 疾患の治療のためのIL−1β及びIL−18に対する抗体
AR082693A1 (es) 2010-08-17 2012-12-26 Roche Glycart Ag Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
JP5758004B2 (ja) 2010-08-24 2015-08-05 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ジスルフィドによって安定化されたFv断片を含む二重特異性抗体
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
KR20130124513A (ko) 2010-11-15 2013-11-14 파이브 프라임 테라퓨틱스, 인크. 가용성 fgfr1 융합 단백질의 상승된 투약량에 의한 암 치료
TWI564304B (zh) 2010-12-30 2017-01-01 武田藥品工業有限公司 抗cd38抗體
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
ES2549638T3 (es) 2011-02-28 2015-10-30 F. Hoffmann-La Roche Ag Proteínas de unión a antígeno
JP6130307B2 (ja) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
ES2692268T3 (es) 2011-03-29 2018-12-03 Roche Glycart Ag Variantes de Fc de anticuerpo
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
EP2694072B1 (de) 2011-04-01 2017-11-29 Genentech, Inc. Kombination von akt-hemmer-verbindung und abirateron zur verwendung in therapeutischen verfahren
CN108178789A (zh) 2011-04-20 2018-06-19 阿塞勒隆制药公司 内皮糖蛋白多肽及其用途
EP3337508A4 (de) * 2015-08-21 2019-04-03 Immunomedics, Inc. Subkutaner monoklonaler anti-hla-dr-antikörper zur behandlung hämatologischer malignitäten
US20140178398A1 (en) 2011-05-03 2014-06-26 Genentech, Inc Vascular disruption agents and uses thereof
WO2012172054A1 (en) 2011-06-16 2012-12-20 Scil Proteins Gmbh Modified multimeric ubiquitin proteins binding vegf-a
EP2726098A1 (de) 2011-06-30 2014-05-07 F.Hoffmann-La Roche Ag Anti-c-met-antikörperformulierungen
US9057728B2 (en) 2011-07-12 2015-06-16 Epitomics, Inc. FACS-based method for obtaining an antibody sequence
EP2551348B1 (de) 2011-07-29 2014-09-24 Icon Genetics GmbH Produktion von galactosylierten N-Glycanen in Pflanzen
RU2014109985A (ru) 2011-08-17 2015-09-27 Дженентек, Инк. Ингибирование ангиогенеза в рефрактерных опухолях
JP6170496B2 (ja) 2011-09-23 2017-07-26 オンコメッド ファーマシューティカルズ インコーポレイテッド Vegf/dll4結合剤およびその使用
CA2850571A1 (en) 2011-10-04 2013-04-11 Icon Genetics Gmbh Nicotiana benthamiana plants deficient in fucosyltransferase activity
CN104066448A (zh) * 2011-10-13 2014-09-24 阿尔皮奥治疗学股份有限公司 眼病的治疗
BR112014008819A2 (pt) 2011-10-13 2017-06-13 Aerpio Therapeutics Inc métodos para o tratamento de síndrome de vazamento vascular e câncer
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
CA2858347A1 (en) 2011-12-05 2013-06-13 Duke University V1v2 immunogens
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
TR201815709T4 (tr) 2011-12-22 2018-11-21 Hoffmann La Roche İyon değişim membranı kromatografisi.
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
EP2797955A2 (de) 2011-12-30 2014-11-05 AbbVie Inc. Immunglobuline mit zweifacher variabler domäne gegen il-13 und/oder il-17
SG11201403927XA (en) 2012-01-13 2014-08-28 Genentech Inc Biological markers for identifying patients for treatment with vegf antagonists
JP6486686B2 (ja) 2012-02-10 2019-03-20 ジェネンテック, インコーポレイテッド 単鎖抗体及び他のヘテロ多量体
EP2819700B1 (de) 2012-02-27 2016-12-21 Universitat de Barcelona Proteaseresistente verbindungen zur verwendung als shuttles durch die blut-hirn-schranke und shuttle-cargo-konstrukte
US20150098988A1 (en) 2012-03-13 2015-04-09 Hoffmann-La Roche Inc. Combination therapy for the treatment of ovarian cancer
RU2017139267A (ru) 2012-03-27 2019-02-12 Дженентек, Инк. Усовершенствованные способы выделения рекомбинантных белков
WO2013148288A1 (en) 2012-03-30 2013-10-03 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
LT2838918T (lt) 2012-04-20 2019-09-10 Merus N.V. Būdai ir priemonės heterodimerinių ig-tipo molekulių gamybai
WO2013170182A1 (en) 2012-05-11 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
CA2874144A1 (en) 2012-05-31 2013-12-05 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
BR112014028376A2 (pt) 2012-06-08 2018-04-24 Hoffmann La Roche métodos para o tratamento de um distúrbio hiperproliferativo, para a determinação dos compostos, para monitorar, para optimizar a eficácia terapêutica e de identificação de um biomarcador; formulação farmacêutica; utilização de uma combinação terapêutica e de gdc-0032, artigo de manufatura, produto e invenção
ES2597228T3 (es) 2012-06-27 2017-01-17 F. Hoffmann-La Roche Ag Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
PL2872534T3 (pl) 2012-07-13 2018-12-31 Roche Glycart Ag Przeciwciała dwuswoiste anty-VEGF/anty-ANG-2 i ich zastosowanie w leczeniu naczyniowych chorób oczu
BR112015002681A2 (pt) 2012-08-07 2018-08-28 Genentech Inc método para tratar um paciente e kit
EP3502267A1 (de) 2012-09-19 2019-06-26 F. Hoffmann-La Roche AG Verfahren und zusammensetzungen zur verhinderung von norleucin-fehlinkorporation in proteine
WO2014071018A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
CN104884472A (zh) 2012-11-01 2015-09-02 艾伯维公司 抗-vegf/dll4双重可变结构域免疫球蛋白及其用途
EP2916835A4 (de) 2012-11-12 2016-07-27 Redwood Bioscience Inc Verbindungen und verfahren zur herstellung eines konjugats
WO2014078733A1 (en) 2012-11-16 2014-05-22 The Regents Of The University Of California Pictet-spengler ligation for protein chemical modification
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
JP2016502850A (ja) 2012-12-18 2016-02-01 ノバルティス アーゲー ヒアルロナンに結合するペプチドタグを使用する組成物及び方法
US9393327B2 (en) 2012-12-19 2016-07-19 Genentech, Inc. Methods and compositions for radiohalogen protein labeling
EP2943190B1 (de) 2013-01-11 2019-01-02 Massachusetts Eye & Ear Infirmary Cyp450-lipid-metaboliten zur unterdrückung von entzündungen und angiogenese
EP2951307A4 (de) 2013-02-04 2016-10-19 Vascular Biogenics Ltd Verfahren zur induzierung der empfänglichkeit für antiangiogenen wirkstoff
SG11201505940WA (en) 2013-02-18 2015-08-28 Vegenics Pty Ltd Ligand binding molecules and uses thereof
MX365567B (es) 2013-03-13 2019-06-07 Genentech Inc Formulaciones de anticuerpo.
WO2014145091A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Cell culture media and methods of antibody production
BR112015023797A2 (pt) 2013-03-15 2017-10-24 Abbvie Inc proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EA201501063A1 (ru) 2013-04-29 2016-05-31 Ф. Хоффманн-Ля Рош Аг СВЯЗЫВАЮЩИЕСЯ С ЧЕЛОВЕЧЕСКИМ FcRn МОДИФИЦИРОВАННЫЕ АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR20160013092A (ko) 2013-05-23 2016-02-03 파이브 프라임 테라퓨틱스, 인크. 암을 치료하는 방법
KR101541478B1 (ko) * 2013-05-31 2015-08-05 동아쏘시오홀딩스 주식회사 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
JP2016528195A (ja) 2013-06-25 2016-09-15 バクシネックス インコーポレーティッド 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−4d阻害分子の使用
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
US20150065781A1 (en) 2013-08-30 2015-03-05 Genentech, Inc. Combination therapy for the treatment of glioblastoma
AR097500A1 (es) 2013-08-30 2016-03-16 Genentech Inc Métodos de diagnóstico y composiciones para el tratamiento de glioblastoma
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
JP6422956B2 (ja) 2013-10-11 2018-11-14 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 多重特異性ドメイン交換共通可変軽鎖抗体
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
JP2017501128A (ja) 2013-11-27 2017-01-12 レッドウッド バイオサイエンス, インコーポレイテッド ヒドラジニル−ピロロ化合物及び複合体を生成するための方法
JP2016530244A (ja) * 2013-12-31 2016-09-29 ディベロップメント センター フォー バイオテクノロジーDevelopment Center For Biotechnology 抗vegf抗体及びその使用
CN106103485A (zh) 2014-01-24 2016-11-09 达纳-法伯癌症研究公司 Pd‑1的抗体分子及其用途
JP6533534B2 (ja) 2014-02-14 2019-06-19 マクロジェニクス,インコーポレーテッド 膠芽腫の治療に使用するための組成物及びその使用
WO2015124588A1 (en) 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway
AU2015229103A1 (en) 2014-03-14 2016-08-04 Immutep S.A.S Antibody molecules to LAG-3 and uses thereof
RU2016141385A3 (de) 2014-03-24 2019-04-03
BR112016022345A2 (pt) 2014-03-31 2017-10-10 Genentech Inc terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
JP2017515811A (ja) 2014-05-01 2017-06-15 ジェネンテック, インコーポレイテッド 抗d因子抗体変異体及びその使用法
CN106456757A (zh) 2014-05-12 2017-02-22 福尔密孔股份公司 含有vegf拮抗剂的预填充塑料注射器
CA2947484A1 (en) 2014-06-06 2015-12-10 Redwood Bioscience, Inc. Anti-her2 antibody-maytansine conjugates and methods of use thereof
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
EP3160991A2 (de) 2014-06-25 2017-05-03 Novartis AG Zusammensetzungen und verfahren für proteine mit langer wirkung
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP2017521075A (ja) 2014-07-09 2017-08-03 ジェネンテック, インコーポレイテッド 細胞バンクの解凍復元を改善するためのpH調整
WO2016011052A1 (en) 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
WO2016025645A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
AU2015301753A1 (en) 2014-08-12 2017-03-02 Massachusetts Institute Of Technology Synergistic tumor treatment with IL-2 and integrin-binding-Fc-fusion protein
EP3191127A1 (de) 2014-09-13 2017-07-19 Novartis AG Kombinationstherapien von egfr-inhibitoren
EA201790737A1 (ru) 2014-10-03 2017-08-31 Новартис Аг Комбинированная терапия
WO2016057846A1 (en) 2014-10-08 2016-04-14 Novartis Ag Compositions and methods of use for augmented immune response and cancer therapy
CA2964367A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
KR20170086036A (ko) 2014-10-17 2017-07-25 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
EP3209769A4 (de) 2014-10-24 2018-07-18 The Board of Trustees of the Leland Stanford Junior University Zusammensetzungen und verfahren zur induzierung der phagozytose von mhc-klasse-i-positiven zellen und verhinderung von anti-cd47/sirpa-resistenz
EA201791029A1 (ru) 2014-11-10 2017-12-29 Дженентек, Инк. Антитела против интерлейкина-33 и их применение
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
JP2017537117A (ja) 2014-12-11 2017-12-14 バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
WO2016106340A2 (en) 2014-12-23 2016-06-30 Genentech, Inc. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
WO2016120753A1 (en) * 2015-01-28 2016-08-04 Pfizer Inc. Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
CN107810197A (zh) 2015-04-24 2018-03-16 豪夫迈·罗氏有限公司 鉴定包含结合多肽的细菌的方法
US20180155429A1 (en) 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
WO2016196389A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
US20170000885A1 (en) 2015-06-08 2017-01-05 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
CN107922502A (zh) 2015-07-14 2018-04-17 百时美施贵宝公司 使用免疫检验点抑制剂治疗癌症的方法
RU2018103960A (ru) 2015-07-29 2019-08-28 Аллерган, Инк. Антитела против ang-2, содержащие только тяжелую цепь
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
HU1500363A2 (en) 2015-08-04 2017-02-28 Richter Gedeon Nyrt Method for increasing the galactose content of recombinant proteins
JP2018523673A (ja) 2015-08-14 2018-08-23 アラーガン、インコーポレイテッドAllergan,Incorporated Pdgfに対する重鎖のみ抗体
WO2017049149A1 (en) 2015-09-17 2017-03-23 Immunogen, Inc. Therapeutic combinations comprising anti-folr1 immunoconjugates
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
US20180230189A1 (en) 2015-09-22 2018-08-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Polypeptides Capable of Inhibiting the Binding Between Leptin and Neuropilin-1
US10072075B2 (en) 2015-09-23 2018-09-11 Genentech, Inc. Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis
WO2017055327A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055321A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of fibroblasts in a tissue sample
WO2017055322A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of neutrophils in a tissue sample
WO2017055320A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017055325A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of nk cells in a tissue sample
WO2017055319A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of b cells in a tissue sample
WO2017055324A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055326A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
EP3362095A1 (de) 2015-10-13 2018-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur behandlung von choroidaler neovaskularisation
EP3368090A1 (de) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-faktor-d-antikörpervarianten-konjugate und verwendungen davon
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
CN108602881A (zh) 2015-10-30 2018-09-28 豪夫迈·罗氏有限公司 抗-因子d抗体制剂
KR20180105123A (ko) 2015-11-18 2018-09-27 에스아이오2 메디컬 프로덕츠, 인크. 안과 제제용 제약 패키지
US20180326126A1 (en) 2015-11-18 2018-11-15 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
US20190000919A1 (en) 2015-11-18 2019-01-03 Formycon Ag Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
BR112018012138A2 (pt) 2015-12-17 2018-12-04 Novartis Ag moléculas de anticorpo para pd-1 e usos das mesmas
EP3407868A1 (de) 2016-01-26 2018-12-05 Formycon AG Flüssigformulierung eines vegf-antagonisten
EP3436610A1 (de) 2016-03-29 2019-02-06 Geltor, Inc. Expression von proteinen in gramnegativen bakterien mit verhältnis von periplasmatischem volumen zu zytoplasmatischem volumen zwischen 0,5:1 und 10:1
MX2018012493A (es) 2016-04-15 2019-06-06 Genentech Inc Métodos para controlar y tratar el cáncer.
JP2019521641A (ja) 2016-04-15 2019-08-08 ジェネンテック, インコーポレイテッド がんを監視及び治療するための方法
WO2018009811A1 (en) 2016-07-08 2018-01-11 Genentech, Inc. Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
WO2018009939A1 (en) 2016-07-08 2018-01-11 Genentech, Inc. Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene.
WO2018011166A2 (en) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
US10253094B2 (en) 2016-07-20 2019-04-09 Aerpio Therapeutics, Inc. Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions
CN106222129A (zh) * 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
WO2018018613A1 (zh) 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
WO2018031865A1 (en) 2016-08-12 2018-02-15 Genentech, Inc. Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
JP2019528074A (ja) * 2016-08-23 2019-10-10 メディミューン リミテッド 抗vegf−a抗体ならびにそれらの使用
US20190300607A1 (en) 2016-10-12 2019-10-03 Daiichi Sankyo Company, Limited Composition containing anti-robo4 antibody and other agents
US10350266B2 (en) 2017-01-10 2019-07-16 Nodus Therapeutics, Inc. Method of treating cancer with a multiple integrin binding Fc fusion protein
WO2018160841A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CA3057590A1 (en) 2017-04-20 2018-10-25 Novartis Ag Sustained release delivery systems comprising traceless linkers
WO2018211529A1 (en) 2017-05-19 2018-11-22 Council Of Scientific & Industrial Research A method for producing refolded recombinant humanized ranibizumab
WO2018217995A1 (en) 2017-05-24 2018-11-29 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
WO2018218013A2 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
US20190031766A1 (en) 2017-06-22 2019-01-31 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag Liquid formulation of a vegf antagonist
WO2019057946A1 (en) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag Multi-cyclic aromatic compounds as factor d inhibitors
WO2019077593A1 (en) 2017-10-20 2019-04-25 Vascular Biogenics Ltd. Diagnostic methods for anti-angiogenic agent therapy
WO2019129677A1 (en) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Anti-vegf antibodies and methods of use
CN110003328A (zh) * 2018-01-05 2019-07-12 百奥泰生物制药股份有限公司 一种长效低毒的重组抗vegf人源化单克隆抗体及其生产方法
WO2019154776A1 (en) 2018-02-06 2019-08-15 F. Hoffmann-La Roche Ag Treatment of ophthalmologic diseases
CN109134651B (zh) * 2018-12-03 2019-02-22 上海复宏汉霖生物技术股份有限公司 一种抗vegf的单克隆抗体及其制备方法和应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
JPS6023084B2 (de) 1979-07-11 1985-06-05 Ajinomoto Kk
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
JPS6289971A (en) * 1985-06-13 1987-04-24 Toray Ind Inc Liquid developer for electrostatic latent image
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
DE68925971D1 (de) 1988-09-23 1996-04-18 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AT189526T (de) * 1988-10-28 2000-02-15 Genentech Inc Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
EP0402226A1 (de) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformationsvektoren für Hefe Yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP1362868A3 (de) * 1991-03-06 2004-02-11 MERCK PATENT GmbH Humanisierte und chimäre monoklonale Antikörper die den Rezeptor für epidermalen Wachstumfaktor (EGF-R) binden
DE69233367T2 (de) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE69233254D1 (de) * 1991-06-14 2004-01-08 Genentech Inc Humanisierter Heregulin Antikörper
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DK0617706T3 (da) 1991-11-25 2001-11-12 Enzon Inc Multivalente antigenbindende proteiner
EP0626012B1 (de) 1992-02-11 2003-07-09 Cell Genesys, Inc. Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
AT399181T (de) * 1992-10-28 2008-07-15 Genentech Inc Verwendung von antagonisten des zellwachstumsfaktors vegf
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
PT1695985E (pt) * 1997-04-07 2011-06-06 Genentech Inc Métodos para formar anticorpos humanizados por mutagénese aleatória
DE122005000026I1 (de) * 1997-04-07 2005-08-04 Genentech Inc Anti-VEGF Antik¦rper.
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies

Also Published As

Publication number Publication date
NO2007015I1 (no) 2008-01-14
NL300193I2 (nl) 2005-10-03
DE69829891T2 (de) 2005-10-06
LU91167I2 (fr) 2005-06-20
CN1259962A (zh) 2000-07-12
DE122005000026I1 (de) 2005-08-04
US20050112126A1 (en) 2005-05-26
DK1325932T3 (da) 2005-05-30
ES2273415T3 (es) 2007-05-01
EP0973804A2 (de) 2000-01-26
EP1650220A2 (de) 2006-04-26
KR20080003453A (ko) 2008-01-07
PT1325932E (pt) 2005-06-30
LU91320I9 (de) 2018-12-31
DK1325932T5 (da) 2005-10-03
HK1084402A1 (en) 2007-11-23
AT349470T (de) 2007-01-15
WO1998045331A2 (en) 1998-10-15
NL300193I1 (nl) 2005-07-01
AU743758B2 (en) 2002-02-07
CA2286330A1 (en) 1998-10-15
NO2007014I2 (no) 2011-02-21
DE122005000050I1 (de) 2005-12-29
EP1325932A3 (de) 2003-10-29
BR9809387A (pt) 2001-09-11
DE69836729D1 (de) 2007-02-08
LU91167A9 (de)
AU7100798A (en) 1998-10-30
NO994869D0 (no) 1999-10-06
WO1998045331A3 (en) 1998-12-03
IL132240D0 (en) 2001-03-19
AT293640T (de) 2005-05-15
EP1325932B9 (de) 2006-07-19
JP2001509817A (ja) 2001-07-24
LU91320A9 (de)
DE69829891D1 (de) 2005-05-25
CA2286330C (en) 2008-06-10
EP1325932A2 (de) 2003-07-09
EP0973804B1 (de) 2006-12-27
EP1650220A3 (de) 2006-05-03
SI1325932T1 (de) 2005-08-31
NO324264B1 (no) 2007-09-17
EP1787999A1 (de) 2007-05-23
EP1787999B1 (de) 2010-08-04
KR100816621B1 (ko) 2008-03-24
TR199903123T2 (xx) 2000-05-22
NZ500078A (en) 2001-10-26
NO2007015I2 (de) 2011-11-28
LTPA2005005I1 (lt) 2017-11-27
NL300278I2 (nl) 2007-10-01
DE69836729T2 (de) 2007-12-13
US7297334B2 (en) 2007-11-20
NL300278I1 (nl) 2007-06-01
LU91320I2 (fr) 2007-04-30
CN100480269C (zh) 2009-04-22
NO2007014I1 (no) 2008-01-14
ES2236634T3 (es) 2005-07-16
KR100870353B1 (ko) 2008-11-25
NO994869L (no) 1999-12-06
HK1023577A1 (en) 2007-03-30
JP3957765B2 (ja) 2007-08-15
US7060269B1 (en) 2006-06-13
DK0973804T3 (da) 2007-05-07
EP1325932B1 (de) 2005-04-20
EP1650220B1 (de) 2007-09-05
BRPI9809387B1 (pt) 2016-11-22
KR20080003452A (ko) 2008-01-07

Similar Documents

Publication Publication Date Title
DE60040872D1 (de) Gerät zur lipolysetherapie
DK0985039T3 (da) Kunstige antistof-polypeptider
DE69839296D1 (de) Lader
DE69841682D1 (de) Chemisch modifizierte polypeptide
DE69841444D1 (de) Verbesserte Stent-Konfgurationen
DE69840916D1 (de) Messgerät
DE69837136D1 (de) Optimierte Leitweglenkung
DE59813885D1 (de) Spannschloss
DE69739832D1 (de) Nähfadenankeranordnung
DK1361751T3 (da) Internettelevisionsprogramquidesystem
DE69840172D1 (de) Rna exportelement
DE69737998D1 (de) Abgabevorrichting
DE69739032D1 (de) Bandfixiervorrichtung
DE69638011D1 (de) Ngriff
DE69638219D1 (de) Teilchentrennverfahren
DE69636827D1 (de) Spreizspektrumübertragungsgerät
DE69636741D1 (de) Bleichkatalysatorteilchen
DE69840618D1 (de) Radargerät
DE69636730D1 (de) Spreizspektrumübertragungssystem
DE69738275D1 (de) Aminoindanderivate
DE69837318D1 (de) Fahrzeuge
DE69637794D1 (de) Sprühpistolekörper
DE69839760D1 (de) Spannvorrichtung
DK1027439T3 (da) Multivalente antigenbindende proteiner
DK0948486T3 (da) Pesticid-1-arylpyrazoler